Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study

202231 citationsJournal Articlegold Open Access

Authors

Themis Bioscience GmbH, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA; Coalition for Epidemic Preparedness Innovations (CEPI).

Good health and well-being

Published in: EBioMedicine

Volume 75, pp. 103810-103810

Field-Weighted Citation Impact: 3.14